We selected nanobodies blocking the activity of hTNFα and IL-12/IL-23 because conventional IgG1 antibodies blocking TNFα and Interleukin (IL-)23 have been approved for the treatment of IBD (16), and therefore these targets are promising candidates to generate small-sized cs130 fusion proteins. The gene discussed is TNF; the disease is inflammatory bowel disease.